Tivic Health Systems Inc. Stock Analysis TIVC

Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company is headquartered in Fremont, California and currently employs 7 full-time employees. The company went IPO on 2021-11-11. The Company’s biopharma program is focused on advancing its drug product candidate, Entolimod, into manufacturing, conducting process validation utilizing the output of such manufacturing with the intent of selling the biologic compounds either inside or outside the United States. The Company’s bioelectronic program is focused on developing non-invasive medical devices that influence biologic functions associated with various diseases and conditions. The company has an over-the-counter device, ClearUP, that treats sinus pain and pressure. The Company’s Toll-like Receptor 5 (TLR5) program’s lead product candidate is the late-stage TLR5 agonist, Entolimod, to treat acute radiation syndrome (ARS) and for remediating side effects of medical radiation and chemotherapy. The firm offers contract development and manufacturing organization through its subsidiary Velocity Bioworks, Inc.